The idea of creating Cerebrum Matter stems from our founder’s personal experience of accompanying her grandmother through a rough journey with Parkinson’s, a decade ago.
Our idea of digital healthcare came to the fore in 2016 when the company’s bootstrapping stage, leading to the idea of a therapy software highly focused on dementia symptoms. The development of the software tunnelled into the R&D process by end of 2017, leading us to start working on conducting a clinical trial with people to develop an evidence-based product aiming sincerely at treating cognitive declination, depression, anger & anxiety, the logical reasoning which are considered to leading onset symptoms of dementia using brainwave analysis.
Dementia is the broad category of neurodegenerative brain diseases that includes such diseases as Alzheimer’s, vascular dementia and Lewy body dementia, etc.
While the use of medication is undoubtedly vital in helping both severe and light sufferers of dementia, Cerebrum Matter believes that dementia prevention is still an underdeveloped form of treatment that could potentially change the way the earlier stages of dementia are treated.
With our advanced brainwave technology we are aiming to provide a personalised experience of cognitive improvement according to each individuals’ brain functionalities.
Changing the Game for Healthy
Cerebrum Matter Founded
COSMA development + Clinical trials
COSMA Soft Launch
Neurofeedback Europe Launch
Cerebrum Matter Active
Neurofeedback Headset Development
Neurofeedback CE Approved
To prevent and reduce the prevalence of the symptoms of early onset dementia, by promoting mental wellness and thus leading to longer and higher quality independent lives to the elderly.
To become a Global leader in the field of cognitive therapy focused brainwave technology, leading to a significant reduction in the estimated numbers of future potential victims of dementia.
Meet the Team
MISS KARTHEKA BOJAN
Kartheka holds an MSc in Biomedical Engineering and has 3-years working experience in the field of
medical devices. She is a first-time Founder and the Inventor of Nanotechnology-based Continuous Glucose Monitoring Device at Nemaura Medical. She holds Pending patent in EEG technology for Alzheimer’s technology and Glucose Monitoring device. Accreditations come in the form of Runner in ‘Space Debris Mitigation Conference’ by NASA, Winner of ‘IEEE Global Humanitarian Technology Conference’ and Published work on Design of Biosensors specific to protein binding and Kinetic Analysis with Fibre optics with Gold Nanoparticle.
MR ANDREW PERKINS
Andrew Perkins has 10 years’ experience in the finance sector and a certified accountant. He has
well-established experience with start-up companies and has been responsible for closing several seeds to series A rounds up to £2.5m funding. His experience extends to coin offerings and has managed successfully up to £8m coin offering in the past 2 years. His finance skillset includes setting up financial models for start-ups with a focus on scalable controls.
MR MOHAMED MAHER
Mohamed Maher is the CEO of Balsamee a mobile IT company taking the mission of developing solutions to
support the delivery of healthcare services in communities outside the traditional healthcare setups. He has extensive experience of working for a venture capital company called Tamkeen Capital and understands the heartline of start-ups.
Mohamed has experience of running NabdaCare, a company that specialised in healthcare imaging and patient-centric digital health solutions and has great experience in marketing of healthcare products with 10 years’ experience in the healthcare sector. He is well connected in the middle east and will help the CM to extend globally with its cognitive products to the east.
MR ADNAN ASHFAQ
REGULATORY DIRECTOR (NON-EXECUTIVE)
Adnan is a Quality & Validation Specialist with over 17 years of validation experience in
Medical Devices, Biotech and Pharmaceutical industries. Adnan will be responsible for quality management systems and will support the entire process of the device development until CE Approval/FDA Approval of the products.
Prof. Mukaetova-Ladinska is chairman of Old Age Psychiatry, University of Leicester, and
clinician at Leicestershire Partnership Trust. She is the clinical advisor of Cerebrum Matter Ltd. She is the clinical lead for validating the COSMA Software in collaboration with University of Leicester. Her areas of academic interest include developing biomarkers with high sensitivity and specificity to detect various forms of dementia and their implementation in the routine clinical setting to monitor the progression of the disease and treatment